Cargando…

Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study

BACKGROUND: This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG). MATERIALS AND METHODS: Sera from 134 patients with MG with varying degrees of disease severity and aut...

Descripción completa

Detalles Bibliográficos
Autores principales: Stascheit, Frauke, Aigner, Annette, Mergenthaler, Philipp, Hotter, Benjamin, Hoffmann, Sarah, Lehnerer, Sophie, Meisel, Christian, Meisel, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875128/
https://www.ncbi.nlm.nih.gov/pubmed/36712429
http://dx.doi.org/10.3389/fneur.2022.1056322
_version_ 1784877893731483648
author Stascheit, Frauke
Aigner, Annette
Mergenthaler, Philipp
Hotter, Benjamin
Hoffmann, Sarah
Lehnerer, Sophie
Meisel, Christian
Meisel, Andreas
author_facet Stascheit, Frauke
Aigner, Annette
Mergenthaler, Philipp
Hotter, Benjamin
Hoffmann, Sarah
Lehnerer, Sophie
Meisel, Christian
Meisel, Andreas
author_sort Stascheit, Frauke
collection PubMed
description BACKGROUND: This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG). MATERIALS AND METHODS: Sera from 134 patients with MG with varying degrees of disease severity and autoantibody (Abs) status were analyzed and compared to controls in a cross-sectional design. Prospectively, we additionally measured serum NfL (sNfl) levels in patients with MG longitudinally for up to 3 years. Based on linear regression, differences between patients and controls were assessed. With correlation coefficients and mixed linear regression, the association among sNfl levels, socio-demographics, disease activity (Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale), Abs-status (acetylcholine receptor antibody (AChR-Abs), muscle-specific receptor tyrosine kinase antibody (MuSK-Abs), lipoprotein-related protein 4 (LRP4), and seronegative), Abs titer, treatment regime (pyridostigmine, steroids, and immunosuppressive therapies), and thymectomy were investigated. RESULTS: sNfl levels were higher in patients with MG compared to controls (median: 11.2 vs. 7.88), where sNfl levels were highest in anti-AChR-Abs positive patients (median 12.6), followed by anti-MuSK-Abs positive, anti-LRP4-Abs positive, and seronegative patients. Adjusting for age and sex, sNfl levels of patients with MG were on average 35% higher compared to controls (35.1, 95% CI: 8.4;68.3) and highest for patients with seronegative MG (44.35; 95% CI 16.47; 78.90). We found no relevant relationship between individual changes in sNfl and changes in QMG and MG-ADL scores. CONCLUSION: sNfl levels are higher in patients with MG than in controls but were not consistently associated with clinical severity. Thus, sNfl is not a suitable biomarker to monitor individual disease progression in patients with MG.
format Online
Article
Text
id pubmed-9875128
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98751282023-01-26 Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study Stascheit, Frauke Aigner, Annette Mergenthaler, Philipp Hotter, Benjamin Hoffmann, Sarah Lehnerer, Sophie Meisel, Christian Meisel, Andreas Front Neurol Neurology BACKGROUND: This study aimed to evaluate the association of neurofilament light chain (Nfl) with neuromuscular destruction and disease severity in the serum of patients with myasthenia gravis (MG). MATERIALS AND METHODS: Sera from 134 patients with MG with varying degrees of disease severity and autoantibody (Abs) status were analyzed and compared to controls in a cross-sectional design. Prospectively, we additionally measured serum NfL (sNfl) levels in patients with MG longitudinally for up to 3 years. Based on linear regression, differences between patients and controls were assessed. With correlation coefficients and mixed linear regression, the association among sNfl levels, socio-demographics, disease activity (Quantitative Myasthenia Gravis (QMG) score and Myasthenia Gravis Activities of Daily Living (MG-ADL) scale), Abs-status (acetylcholine receptor antibody (AChR-Abs), muscle-specific receptor tyrosine kinase antibody (MuSK-Abs), lipoprotein-related protein 4 (LRP4), and seronegative), Abs titer, treatment regime (pyridostigmine, steroids, and immunosuppressive therapies), and thymectomy were investigated. RESULTS: sNfl levels were higher in patients with MG compared to controls (median: 11.2 vs. 7.88), where sNfl levels were highest in anti-AChR-Abs positive patients (median 12.6), followed by anti-MuSK-Abs positive, anti-LRP4-Abs positive, and seronegative patients. Adjusting for age and sex, sNfl levels of patients with MG were on average 35% higher compared to controls (35.1, 95% CI: 8.4;68.3) and highest for patients with seronegative MG (44.35; 95% CI 16.47; 78.90). We found no relevant relationship between individual changes in sNfl and changes in QMG and MG-ADL scores. CONCLUSION: sNfl levels are higher in patients with MG than in controls but were not consistently associated with clinical severity. Thus, sNfl is not a suitable biomarker to monitor individual disease progression in patients with MG. Frontiers Media S.A. 2023-01-11 /pmc/articles/PMC9875128/ /pubmed/36712429 http://dx.doi.org/10.3389/fneur.2022.1056322 Text en Copyright © 2023 Stascheit, Aigner, Mergenthaler, Hotter, Hoffmann, Lehnerer, Meisel and Meisel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Stascheit, Frauke
Aigner, Annette
Mergenthaler, Philipp
Hotter, Benjamin
Hoffmann, Sarah
Lehnerer, Sophie
Meisel, Christian
Meisel, Andreas
Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title_full Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title_fullStr Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title_full_unstemmed Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title_short Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
title_sort serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case–control study
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875128/
https://www.ncbi.nlm.nih.gov/pubmed/36712429
http://dx.doi.org/10.3389/fneur.2022.1056322
work_keys_str_mv AT stascheitfrauke serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT aignerannette serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT mergenthalerphilipp serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT hotterbenjamin serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT hoffmannsarah serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT lehnerersophie serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT meiselchristian serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy
AT meiselandreas serumneurofilamentlightchaininmyastheniagravissubgroupsanexploratorycohortandcasecontrolstudy